Is additional 5-day vasoactive drug therapy necessary for acute variceal bleeding after successful endoscopic hemostasis?
Authors:
Open Access
- 1 October 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (41) , e12826
Abstract
Background: Vasoactive drugs and endoscopic therapy have been widely used in the management of acute variceal bleeding of cirrhosis patients. The current standard regimen of vasoactive drugs is in combination with endoscopic therapy and continues for up to 5 days; however, the necessity of vasoactive drugs after endoscopic hemostasis was still controversial. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and optimal duration of adjuvant vasoactive drugs after hemorrhage control by endoscopic therapy. Methods: A search was conducted of PubMed, EMBASE, and Cochrane Library databases until June, 2018. Lan DeMets sequential monitoring boundary was constructed to assess the reliability and conclusiveness of our major results. Results: Seven studies (639 patients) and 4 studies (435 patients) were included in the analyses to evaluate the efficacy and optimal duration of adjuvant vasoactive drugs therapy, respectively. Our analyses showed that adjuvant vasoactive drugs facilitated endoscopic hemostasis and reduced very early re-bleeding rate both in sclerotherapy (risk ratio [RR] 0.51, 95% confidence interval [CI] 0.34–0.78, P = .23, I 2 = 31%) and band ligation (RR 0.48, 95% CI 0.27–0.83, P = .07, I 2 = 62%). However, the 3 to 5-day therapy duration was not superior to a shorter course in very early re-bleeding rate and mortality rate in 42 days (RR 1.77, 95% CI 0.64–4.89, P = .70, I 2 = 0%; RR 0.95, 95% CI 0.43–2.13, P = .81, I 2 = 0%, respectively). Conclusion: Additional 5-day vasoactive drug after endoscopic hemostasis may significantly ameliorate very early re-bleeding rate, However, the 3 to 5 days’ adjuvant regimen was not superior to a shorter course.Keywords
This publication has 28 references indexed in Scilit:
- Meta‐analysis: vasoactive medications for the management of acute variceal bleedsAlimentary Pharmacology & Therapeutics, 2012
- Short course adjuvant terlipressin in acute variceal bleeding: A randomized double blind dummy controlled trialJournal of Hepatology, 2012
- Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosisHepatology, 2004
- Octreótido, tratamiento endoscópico o ambos en la hemorragia variceal activa enpacientes cirróticos: estudio multicéntricoRevista médica de Chile, 2004
- Endoscopic treatment versus endoscopic plus pharmacologic treatment for variceal bleedingJournal of Hepatology, 2002
- Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysisHepatology, 2002
- Early Administration of Vapreotide for Variceal Bleeding in Patients with CirrhosisNew England Journal of Medicine, 2001
- Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertensionGastroenterology, 2001
- Sclerotherapy with or without Octreotide for Acute Variceal BleedingNew England Journal of Medicine, 1995
- Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double-blind, placebo-controlled, multicenter trial*1Hepatology, 1995